ITeva's TV-46000/mdc-IRM shows significant action in schizophrenia

Israel’s Teva Pharmaceutical Industries (NYSE: TEVA) has announced results from the pivotal Phase III Risperidone Subcutaneous Extended-release (RISE) study comparing TV-46000/mdc-IRM once monthly (q1m) and TV-46000/mdc-IRM once every two months (q2m) with placebo (1:1:1) in patients with schizophrenia who underwent stabilization on oral risperidone, which showed the treatment (overall, q1m or q2m) significantly prolonged time to relapse, decreased proportions of patients with impending relapse at week 24 and demonstrated significant increase in proportions maintaining stability.

These findings, among others, were presented during the poster session at the 2021 Psych Congress Annual Meeting taking place October 29-November 1, 2021 in San Antonio, Texas, USA.

“Relapse rates among people living with schizophrenia are quite staggering, ranging between 50% and 92% globally. It is crucial to provide patients and prescribers with treatment options that have the potential to reduce relapse rates to help manage and stabilize the disease over time,” said Dr Eran Harary, vice president, global head of specialty R&D at Teva. “Coming off the heels of the recent FDA acceptance of our New Drug Application, we’re proud to be sharing our Phase III data at this year’s Psych Congress. We are committed to investigating the full potential of our subcutaneous long-acting injectable (LAI) formulation of risperidone for the treatment of this complex and burdensome illness.”